Inhibitory effect of clofibrate on arginine-induced insulin secretion in chemical diabetes.
Clofibrate 3 g/die for 10 consecutive days, significantly reduced arginine-induced IRI release in chemical diabetics and in normal controls, whether of normal body weight or obese. Blood glucose levels were not affected by clofibrate. In agreement with previous findings, it would appear that clofibrate, administered for short periods does not lead to a decrease in glucose tolerance. However, studies relating to the effect of chronic clofibrate administration in chemical diabetes are needed in order to be sure that prolonged inhibition of IRI secretion does not lead to overt diabetes.
D000941:Antigens; D001120:Arginine; D001786:Blood Glucose / Q000378:metabolism; D002994:Clofibrate / Q000494:pharmacology*; D003920:Diabetes Mellitus / Q000503:physiopathology*; D006801:Humans; D007328:Insulin / Q000097:blood*; D009765:Obesity
D000941:Antigens; D001786:Blood Glucose; D007328:Insulin; D001120:Arginine; D002994:Clofibrate